Q2-Q3 Earnings Roundup: Moog Raises Guidance, WisdomTree Beats, RBC Bearings Strong—While TXNM and Moderna Miss Estimates

A cross-sector earnings review reveals Moog Inc and WisdomTree both posting beats and strong GF Scores, RBC Bearings delivering solid Q1 results, while TXNM Energy and Moderna reported Q2 misses with elevated valuation flags from GuruFocus—painting a mixed picture of corporate health heading into earnings season's second half.

• Moog Inc (MOG.A) Q3 EPS beat at $4.74, raised full-year guidance, with GF Score 78/100; WisdomTree Q2 EPS $0.28 beat with GF Score 87/100
• TXNM Energy Q2 EPS $0.64 on revenue of $582 million missed expectations, with GF Score 73 flagging 28.4% overvaluation versus fair value
• Moderna Q2 EPS of -$1.97 missed estimates on revenue of $1.45 billion, while RBC Bearings Q1 EPS $3.20 on $519.5 million revenue came in above consensus

Among the session's earnings reporters, Moog Inc stood out with a Q3 EPS beat of $4.74 and raised full-year guidance—a combination that typically drives sustained institutional buying. WisdomTree's Q2 EPS of $0.28 beat on revenue of $177.2 million, and its GF Score of 87/100 places it among the better-positioned financial services companies by composite quality metrics. RBC Bearings' Q1 result of $3.20 EPS on $519.5 million revenue also cleared consensus, reflecting continued strength in precision components demand from aerospace and industrial end markets.

The misses in this batch provide a counterbalance. TXNM Energy's Q2 EPS of $0.64 on $582.7 million revenue fell short of expectations, with GuruFocus flagging a 28.4% overvaluation versus fair value on a GF Score of 73/100—a yellow flag combination that raises questions about the utility's premium pricing relative to its regulated earnings power. Moderna's Q2 EPS of -$1.97 missed estimates on $1.45 billion revenue, reflecting the ongoing normalization of COVID-era demand and the company's difficult transition toward a sustainable pipeline-based revenue model.

Taken together, this earnings cohort illustrates the bifurcation within mid-cap industrials, financials, and healthcare: companies with strong GF Scores and guidance raises are trading at premium valuations for clear operational reasons, while those missing estimates face valuation compression risk even at already-discounted multiples. The GuruFocus overvaluation flags across TXNM and Moderna are notable as investor patience with misses runs thinner in a higher-for-longer rate environment.

Source: GuruFocus | 5 sources